Research programme: siRNA therapeutics - Suzhou Ribo Life Sciences

Drug Profile

Research programme: siRNA therapeutics - Suzhou Ribo Life Sciences

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suzhou Ribo Life Science
  • Class RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Fibrosis; HIV infections; Liver cancer; Pancreatic cancer

Most Recent Events

  • 26 Jul 2016 Research programme: siRNA therapeutics - Suzhou Ribo Life Sciences is available for licensing - http://www.ribolia.com/en/development/index.aspx?BasicClassId=552&HeadID=5
  • 26 Jul 2016 Early research in Fibrosis in China (Parenteral)
  • 26 Jul 2016 Early research in HIV infections in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top